Alnylam Pharmaceuticals and Agilent Technologies sign manufacturing services agreement

Alnylam Pharmaceuticals and Agilent Technologies entered a manufacturing services agreement for the supply of patisiran drug substance by Agilent. The initial term is 5 years, subject to automatic renewal for 2-year terms.

“Pursuant to deal, Agilent has agreed to manufacture, supply to co, active pharmaceutical ingredients required for patisiran for commercial sale.”reuters.com

• 1 source
• reuters.comAlnylam Pharma Co, Agilent Technologies Entered Manufacturing Services Agreement Providing For Supply Of Patisiran Drug Substance By AgilentApr 3, 2018

Summarized from public sources; check the original articles before acting on it.